Scholarlink

<p>Doxecitine and doxribtimine (KYGEVVI<sup>®</sup>) are pyrimidine nucleosides developed by UCB for the treatment of thymidine kinase&#xa0;2 deficiency (TK2d). In November 2025, doxecitine and doxribtimine received its first approval in the USA for the treatment of TK2d in adult and pediatric patients with an age of symptom onset on or before 12&#xa0;years. This article summarizes the milestones in the development of doxecitine and doxribtimine leading to this first approval for TK2d.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Doxecitine and Doxribtimine: First Approval

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月28日

查看全文
  • Hannah A. Blair

摘要

Doxecitine and doxribtimine (KYGEVVI®) are pyrimidine nucleosides developed by UCB for the treatment of thymidine kinase 2 deficiency (TK2d). In November 2025, doxecitine and doxribtimine received its first approval in the USA for the treatment of TK2d in adult and pediatric patients with an age of symptom onset on or before 12 years. This article summarizes the milestones in the development of doxecitine and doxribtimine leading to this first approval for TK2d.